Home
/
ENDONOVO THERAPEUTICS, INC.
/
Financials
/
Quarterly
ENDONOVO THERAPEUTICS, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that ENDONOVO THERAPEUTICS, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2018
Sep 30, 2018
$21.3K
Nov 13, 2018
Q2
2018
Jun 30, 2018
$12.9K
Aug 13, 2018
Q1
2018
Mar 31, 2018
$7.0K
May 18, 2018
Q3
2013
Sep 30, 2013
$0
Dec 18, 2013
Q2
2013
Jun 30, 2013
$0
Aug 28, 2013
Q1
2013
Mar 31, 2013
$0
Jun 21, 2013
Q3
2013
Sep 30, 2012
$7.2K
Dec 18, 2013
Q2
2013
Jun 30, 2012
$8.1K
Aug 28, 2013
Q1
2013
Mar 31, 2012
$1.7K
Jun 21, 2013
Q1
2012
Mar 31, 2011
$0
May 21, 2012
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2023
Sep 30, 2023
$1.5K
Dec 29, 2023
Q2
2023
Jun 30, 2023
$45.2K
Aug 21, 2023
Q1
2023
Mar 31, 2023
$87.5K
May 22, 2023
Q3
2023
Sep 30, 2022
$11.0K
Dec 29, 2023
Q2
2023
Jun 30, 2022
$650
Aug 21, 2023
Q1
2023
Mar 31, 2022
$2.3K
May 22, 2023
Q3
2022
Sep 30, 2021
$7.8K
Nov 21, 2022
Q2
2022
Jun 30, 2021
$30.3K
Aug 22, 2022
Q1
2022
Mar 31, 2021
$34.7K
May 19, 2022
Q3
2021
Sep 30, 2020
$40.0K
Nov 19, 2021
Q2
2021
Jun 30, 2020
$44.6K
Aug 23, 2021
Q1
2021
Mar 31, 2020
$69.7K
May 24, 2021
Q3
2020
Sep 30, 2019
$54.0K
Nov 19, 2020
Q2
2020
Jun 30, 2019
$62.7K
Aug 19, 2020
Q1
2020
Mar 31, 2019
$45.0K
Jun 12, 2020
Q3
2019
Sep 30, 2018
$21.3K
Nov 19, 2019
Q2
2019
Jun 30, 2018
$12.9K
Aug 13, 2019
Q1
2019
Mar 31, 2018
$7.0K
May 9, 2019
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2016
Mar 31, 2016
$0
May 27, 2016
Q3
2016
Sep 30, 2015
($400)
Nov 14, 2016
Q2
2016
Jun 30, 2015
$1.9K
Aug 12, 2016
Q1
2016
Mar 31, 2015
$2.7K
May 27, 2016
Q3
2015
Sep 30, 2014
$20.6K
Nov 23, 2015
Q2
2015
Jun 30, 2014
$16.4K
Aug 19, 2015
Q1
2015
Mar 31, 2014
$17.8K
Jun 15, 2015
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2023
Sep 30, 2023
($766.2K)
Dec 29, 2023
Q3
2023
Jun 30, 2023
$2.06M
Dec 29, 2023
Q2
2023
Jun 30, 2023
$2.06M
Aug 21, 2023
Q2
2023
Mar 31, 2023
$7.23M
Aug 21, 2023
Q1
2023
Mar 31, 2023
$7.23M
May 22, 2023
Q3
2023
Mar 31, 2023
$7.23M
Dec 29, 2023
Q3
2023
Sep 30, 2022
($603.4K)
Dec 29, 2023
Q3
2023
Jun 30, 2022
($2.53M)
Dec 29, 2023
Q2
2023
Jun 30, 2022
($2.53M)
Aug 21, 2023
Q3
2023
Mar 31, 2022
($2.41M)
Dec 29, 2023
Q1
2023
Mar 31, 2022
($2.41M)
May 22, 2023
Q2
2023
Mar 31, 2022
($2.41M)
Aug 21, 2023
Q3
2022
Sep 30, 2021
($1.52M)
Nov 21, 2022
Q3
2022
Jun 30, 2021
($1.30M)
Nov 21, 2022
Q2
2022
Jun 30, 2021
($1.30M)
Aug 22, 2022
Q3
2022
Mar 31, 2021
($2.68M)
Nov 21, 2022
Q1
2022
Mar 31, 2021
($2.68M)
May 19, 2022
Q2
2022
Mar 31, 2021
($2.68M)
Aug 22, 2022
Q3
2021
Sep 30, 2020
($1.07M)
Nov 19, 2021
Q3
2021
Jun 30, 2020
($1.63M)
Nov 19, 2021
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2023
Sep 30, 2023
($472.8K)
Dec 29, 2023
Q2
2023
Jun 30, 2023
($1.13M)
Aug 21, 2023
Q1
2023
Mar 31, 2023
($529.3K)
May 22, 2023
Q3
2023
Sep 30, 2022
($496.8K)
Dec 29, 2023
Q2
2023
Jun 30, 2022
($1.80M)
Aug 21, 2023
Q1
2023
Mar 31, 2022
($485.8K)
May 22, 2023
Q3
2022
Sep 30, 2021
($692.3K)
Nov 21, 2022
Q2
2022
Jun 30, 2021
($570.1K)
Aug 22, 2022
Q1
2022
Mar 31, 2021
($590.4K)
May 19, 2022
Q3
2021
Sep 30, 2020
($946.8K)
Nov 19, 2021
Q2
2021
Jun 30, 2020
($601.8K)
Aug 23, 2021
Q1
2021
Mar 31, 2020
($679.6K)
May 24, 2021
Q3
2020
Sep 30, 2019
($1.29M)
Nov 19, 2020
Q2
2020
Jun 30, 2019
($974.8K)
Aug 19, 2020
Q1
2020
Mar 31, 2019
($813.0K)
Jun 12, 2020
Q3
2019
Sep 30, 2018
($1.04M)
Nov 19, 2019
Q2
2019
Jun 30, 2018
($816.7K)
Aug 13, 2019
Q1
2019
Mar 31, 2018
($1.28M)
May 9, 2019
Q3
2018
Sep 30, 2017
($1.04M)
Nov 13, 2018
Q2
2018
Jun 30, 2017
($2.18M)
Aug 13, 2018